Publications

2018 | 2017 |2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008 | 2007 | 20062005 | 2004 | 2003 |
Prior to 2000 | Clinical Abstracts|
 
    
  

2018

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology. 2018 Feb 1;36(4):359-366.

Pure E, Hingorani SR. Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy.Trends Cancer. 2018 Mar 11;4(4):273-277.

Farr N, Wang YN, D'Andrea S, Starr F, Partanen A, Gravelle KM, McCune JS, Risler LJ, Whang SG, Chang A, Hingorani SR, Lee D, Hwang JH.Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.Int J Hyperthermia. 2017 Jul 17; 34(3):284-291.

 


2017

Whittle MC, Hingorani SR. Understanding disease biology and informing the management of pancreas cancer with preclinical model systems. Cancer Journal. 2017 Nov/Dec;23(6):326-332.

Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunology Research. 2017 Nov;5(11):978-991.

Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).Curr Oncol Rep. 2017 Jul;19(7):47.

Wu L, Wu IC, DuFort CC, Carlson MA, Wu X, Chen L, Kuo CT, Qin Y, Yu J, Hingorani SR, Chiu DT. Photostable ratiometric Pdot probe for in vitro and in vivo imaging of hypochlorous acid. Journal of the American Chemical Society. 2017 May 24;139(20):6911-18.

Whittle MC, Hingorani SR. Chapter 21: Runx3 and Cell Fate Decisions in Pancreas Cancer. In: RUNX Proteins in Development and Cancer, Advances in Experimental Medicine and Biology 962. Y. Groner et al., eds., Springer Nature Singapore Pte Ltd., 2017. doi: 10.1007/978-981-10-3233-2_21.

Zhong Y, Macgregor-Das AM, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA. Mutant p53 together with TGFβ signaling influence organ-specific hematogenous colonization patterns of pancreatic cancer. Clinical Cancer Research. 2017 Mar 15;23(6):1607-20.


2016

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clinical Cancer Research. 2016 Jun 15;22(12):2848-54.

DuFort CC, Hingorani SRTension and transformation in pancreas cancer: Can phenotype break free from the chrysalis of genotype? Cancer Cell. 2016 Jun 13;29(6):780-2.

DuFort CC, DelGiorno KE, Carlson MA, Osgood RJ, Zhao C, Huang Z, Thompson CB, Connor RJ, Thanos CD, Scott Brockenbrough J, Provenzano PP, Frost GI, Michael Shepard H, Hingorani SRInterstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophysical Journal. 2016 May 10;110(9):2106-19. PMCID: PMC4939548

Kuo CT, Thompson AM, Gallina ME, Ye F, Johnson ES, Sun W, Zhao M, Yu J, Wu IC, Fujimoto B, DuFort CC, Carlson MA, Hingorani SR, Paguirigan AL, Radich JP, Chiu DT. Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable Pdots. Nature Communications. 2016 Apr 27;7:11468. PMCID: PMC4853474

DuFort CC, DelGiorno KE, Hingorani SRMounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology. 2016 Apr 9;150:1545-57. PMCID: PMC4957812


2015

Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell. 2015;28(5):638-52. PMCID: PMC4724422

Whittle MC, Hingorani SR. Disconnect between EMT and metastasis in pancreas cancer. Oncotarget. 2015;6(31):30445-6. PMCID: PMC4741540

Hingorani SR. Intercepting cancer communiques: exosomes as heralds of malignancy. Cancer Cell. 2015;28(2):151-3.

Whittle MC, Hingorani SRRUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. Molecular & Cellular Oncology. 2015 Jul 29;3(2):e1076588. PMCID: PMC4905377

Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell. 2015;161(6):1345-60. PMCID: PMC4458240

Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clinical Cancer Research. 2015;21(7):1764-71. PMCID: PMC4391639

Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. The Oncologist. 2015;20(2):143-50. PMCID: PMC4319641


2014

Mirus JE, Zhang Y, Hollingsworth MA, Solan JL, Lampe PD, Hingorani SR. Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease. Molecular & Cellular Proteomics. 2014;13(12):3484-96. PMCID: PMC4256499

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63(11):1769-81. PMCID: PMC4340484

Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clinical Cancer Research. 2014;20(20):5157-70. PMCID: PMC4269607

DelGiorno KE, Carlson MA, Osgood R, Provenzano PP, Brockenbough JS, Thompson CB, Shepard HM, Frost GI, Potter JD, Hingorani SR. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning. Cancer Cell. 2014;26(1):16-7. PMCID: PMC4465109

Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR. Stromal reengineering to treat pancreas cancer. Carcinogenesis. 2014;35(7):1451-60. PMCID: PMC4076816

Hingorani SR. Cellular and molecular conspirators in pancreas cancer. Carcinogenesis. 2014;35(7):1435.

Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews. 2014;257(1):145-64. PMCID: PMC4015625


2013

Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, PA). 2013;6(10):1074-83. PMCID: PMC4165552

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G. Hypoxia triggers hedgehog-mediated tumor stromal interactions in pancreatic cancer. Cancer Research. 2013;73(11):3235-47. PMCID: PMC3782107

Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis. 2013;34(4):858-63. PMCID: PMC3616675

Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British Journal of Cancer. 2013;108(1):1-8. PMCID: PMC3553539


2012

Hingorani SR, Potter JD. Pancreas cancer meets the thunder god. Science Translational Medicine. 2012;4(156):156ps21.

Solan JL, Hingorani SR, Lampe PD. Changes in connexin43 expression and localization during pancreatic cancer progression. The Journal of Membrane Biology. 2012;245(5-6):255-62. PMCID: PMC3518378

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418-29. PMCID: PMC3371414


2010

Goicoechea SM, Bednarski B, Stack C, Cowan DW, Volmar K, Thorne L, Cukierman E, Rustgi AK, Brentnall T, Hwang RF, McCulloch CA, Yeh JJ, Bentrem DJ, Hochwald SN, Hingorani SR, Kim HJ, Otey CA. Isoform-specific upregulation of palladin in human and murine pancreas tumors. PloS One. 2010;5(4):e10347. PMCID: PMC2859948

Hingorani SR. Chapter 4, A New Preclinical Paradigm for Pancreas Cancer. In: Drug Discovery in Pancreatic Cancer: Models and Techniques. Haiyong Han and Paul J. Grippo, eds. Springer Press, New York, NY, pp.73-90, 2010.


2009

Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Journal of Clinical Oncology. 2009;27(33):5660-9.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, NY). 2009; 324(5933):1457-61. PMCID: PMC2998180


2008

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clinical Cancer Research. 2008;14(15):4836-42.

Hingorani SR. Chapter 10, From Inception to Invasion: Modeling Pathways to Pancreatic Cancer. In: Pancreatic Cancer. Leach S.A. and Lowy A., eds. Springer Press, Chicago, IL, p.159-179. 2008.


2007

Izeradjene K, Hingorani SR. Targets, trials, and travails in pancreas cancer. Journal of the National Comprehensive Cancer Network. 2007;5(10):1042-53.

Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research. 2007;67(19):9518-27.

Hingorani SR. Location, location, location: precursors and prognoses for pancreatic cancer. Gastroenterology. 2007;133(1):345-50.

Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Research. 2007;67(13):6075-82.

Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11(3):229-43.


2006

Deramaudt TB, Takaoka M, Upadhyay R, Bowser MJ, Porter J, Lee A, Rhoades B, Johnstone CN, Weissleder R, Hingorani SR, Mahmood U, Rustgi AK. N-cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-RASG12V and p53V143A in promoting pancreatic cell migration, invasion, and tissue architecture disruption. Molecular & Cellular Biology. 2006;26(11):4185-200. PMCID: PMC1489079


2005

Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8(4):311-21.

Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-83.

Hingorani SR. Modeling Pancreatic Ductal Adenocarcinoma in the Mouse. In: Exocrine Pancreas
Cancer. Gress T.M., Neoptolemos J.P., Lemoine N.R., Real F.X., eds. The European Pancreatic Cancer-Research Cooperative (EPC-RC), Felsenstein CCCP Publishing, Hannover, pp.152-171, 2005.

Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. In: Cold Spring Harbor Symposia on Quantitative Biology, Volume LXX. Stillman B. and Stewart D., eds. Cold Spring Harbor Laboratory Press, Woodbury, NY, pp.65-72, 2005.


2004

Wang LF, Hingorani SR, Tuveson DA. Detecting and diagnosing ampullary neoplasms. Cancer Biology & Therapy. 2004;3(7):657-9.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4):375-87.

Hingorani SR. New pathways to pancreatic cancer. Cancer Biology & Therapy. 2004;3(2):170-2.


2003

Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-50.

Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research. 2003;63(17):5198-202.

Karlseder J, Kachatrian L, Takai H, Mercer K, Hingorani S, Jacks T, de Lange T. Targeted deletion reveals an essential function for the telomere length regulator Trf1. Molecular & Cellular Biology. 2003;23(18):6533-41. PMCID: PMC193696

Hingorani SR, Tuveson DA. Targeting oncogene dependence and resistance. Cancer Cell. 2003;3(5):414-7.

Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics & Development. 2003;13(1):6-13.

Hingorani SR, Tuveson DA. In search of an early warning system for pancreatic cancer. Cancer Biology & Therapy. 2003;2(1):84-6.


Prior to 2000

Hingorani SR, Agnew WS. Assay and purification of neuronal receptors for inositol 1,4,5-trisphosphate. Methods in Enzymology. 1992;207:573-91.

Hingorani SR, Agnew WS. A rapid ion-exchange assay for detergent-solubilized inositol 1,4,5-trisphosphate receptors. Analytical Biochemistry. 1991;194(1):204-13.


Clinical Abstracts

Hingorani SR, Bullock AJ, Seery TE, Zheng L, Sigal D, Ritch PS, Braiteh FS, Zalupski M, Bahary N, Harris WP, Pu J, Aldrich C, Khelifa S, Wu XW, Baranda J, Jiang P, Hendifar AE. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 35, 2017 (suppl; abstr 4008).

Hingorani SR, Harris WP, Seery TE, Zheng L, Sigal D, Hendifar AE, Braiteh F, Zalupski M, Baron A, Bahary N, Gillam AW, LoConte N, Springett G, Ritch P, Hezel AF, Ma WW, Bathini V, Wu XW, Jiang P, Bullock A. Interim results of a randomized phase II study of PEGPH20 added to nab paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology 34, 2016 (suppl 4S; abstr 439).

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin S, Gladkov O, Holcombe RF, Jiang P, Devoe CE. Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology 33, 2015 (suppl 3; abstr 359).

Harris WP, Hingorani SR, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin S, Gladkov O, Holcombe RF, Jiang P, Maneval DC, Korn RI, Shepard HM, Devoe CE. Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA). Journal of Clinical Oncology 33, 2015 (suppl 3; abstr 300).

Hingorani SR, Harris WP, Hendifar AE, Bullock AJ, Wu XW, Huang Y, Jiang P. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. Journal of Clinical Oncology 33, 2015 (suppl; abstr 4006).

Harris WP, Hingorani SR, Beck JT, Berdov BA, Wagner SA, Pshevlotsky E, Tjulandin S, Gladkov O, Holcombe RF, Jiang P, Maneval DC, Zhu J, Devoe CE. Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer. Journal of Clinical Oncology 31, 2013 (suppl; abstr e15005).

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky E, Tjulandin S, Gladkov O, Holcombe RF, Schechet L, Jiang P, Zhu J, Devoe CE. A phase 1b study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. European Journal of Cancer, Volume 49 Supplement 2, 2013.

Moore MJ, Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Hon JK, Biakhov M, Hingorani SR, Ganju V, Weekes CD, Scheithauer W, Ramanathan RK, Tabernero J, Goldstein D, Wei X, Romano A. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). Journal of Clinical Oncology 31, 2013 (suppl; abstr 4059).

Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin S, Gladkov O, Holcombe RF, Jiang P, Maneval DC, Zhu J, Devoe CE. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology 31, 2013 (suppl; abstr 4010).